Morgens Waterfall Vintiadis Co Inc adds Merck & Co. (MRK) to its portfolio

Merck & Co. (MRK) : Morgens Waterfall Vintiadis Co Inc added new position in Merck & Co. during the most recent quarter end. The investment management firm now holds 36,500 shares of Merck & Co. which is valued at $2,260,445 , the company said in a statement filed on Oct 12, 2016 with the SEC.Merck & Co. makes up approximately 2.04% of Morgens Waterfall Vintiadis Co Inc’s portfolio.

Other Hedge Funds, Including , Genesee Valley Trust Co reduced its stake in MRK by selling 3,741 shares or 14.28% in the most recent quarter. The Hedge Fund company now holds 22,451 shares of MRK which is valued at $1,390,390. Merck & Co. makes up approx 0.90% of Genesee Valley Trust Co’s portfolio.Raymond James Trust N.a. boosted its stake in MRK in the latest quarter, The investment management firm added 2,790 additional shares and now holds a total of 340,535 shares of Merck & Co. which is valued at $21,760,187. Merck & Co. makes up approx 1.88% of Raymond James Trust N.a.’s portfolio.Lgt Capital Partners Ltd. boosted its stake in MRK in the latest quarter, The investment management firm added 1,800 additional shares and now holds a total of 319,120 shares of Merck & Co. which is valued at $20,391,768. Merck & Co. makes up approx 2.87% of Lgt Capital Partners Ltd.’s portfolio. Contravisory Investment Management added MRK to its portfolio by purchasing 49 company shares during the most recent quarter which is valued at $3,131.

Merck & Co. closed down -1.97 points or -3.08% at $61.93 with 1,39,55,380 shares getting traded on Tuesday. Post opening the session at $63.53, the shares hit an intraday low of $61.75 and an intraday high of $63.55 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Merck & Co. was Upgraded by BofA/Merrill to ” Buy” on Oct 13, 2016. Company shares were Reiterated by Barclays on Sep 9, 2016 to “Overweight”, Firm has raised the Price Target to $ 72 from a previous price target of $66 .Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.